Antifungal  ||| S:0 E:11 ||| JJ
drug  ||| S:11 E:16 ||| NN
resistance ||| S:16 E:26 ||| NN
:  ||| S:26 E:28 ||| :
mechanisms ||| S:28 E:38 ||| NNS
,  ||| S:38 E:40 ||| ,
epidemiology ||| S:40 E:52 ||| NN
,  ||| S:52 E:54 ||| ,
and  ||| S:54 E:58 ||| CC
consequences  ||| S:58 E:71 ||| NNS
for  ||| S:71 E:75 ||| IN
treatment  ||| S:75 E:85 ||| NN
Antifungal  ||| S:85 E:96 ||| NNP
resistance  ||| S:96 E:107 ||| NN
continues  ||| S:107 E:117 ||| VBZ
to  ||| S:117 E:120 ||| TO
grow  ||| S:120 E:125 ||| VB
and  ||| S:125 E:129 ||| CC
evolve  ||| S:129 E:136 ||| VB
and  ||| S:136 E:140 ||| CC
complicate  ||| S:140 E:151 ||| VB
patient  ||| S:151 E:159 ||| JJ
management ||| S:159 E:169 ||| NN
,  ||| S:169 E:171 ||| ,
despite  ||| S:171 E:179 ||| IN
the  ||| S:179 E:183 ||| DT
introduction  ||| S:183 E:196 ||| NN
of  ||| S:196 E:199 ||| IN
new  ||| S:199 E:203 ||| JJ
antifungal  ||| S:203 E:214 ||| JJ
agents ||| S:214 E:220 ||| NNS
.  ||| S:220 E:222 ||| .
In  ||| S:222 E:225 ||| IN
vitro  ||| S:225 E:231 ||| JJ
susceptibility  ||| S:231 E:246 ||| JJ
testing  ||| S:246 E:254 ||| NN
is  ||| S:254 E:257 ||| VBZ
often  ||| S:257 E:263 ||| RB
used  ||| S:263 E:268 ||| VBN
to  ||| S:268 E:271 ||| TO
select  ||| S:271 E:278 ||| VB
agents  ||| S:278 E:285 ||| NNS
with  ||| S:285 E:290 ||| IN
likely  ||| S:290 E:297 ||| JJ
activity  ||| S:297 E:306 ||| NN
for  ||| S:306 E:310 ||| IN
a  ||| S:310 E:312 ||| DT
given  ||| S:312 E:318 ||| VBN
infection ||| S:318 E:327 ||| NN
,  ||| S:327 E:329 ||| ,
but  ||| S:329 E:333 ||| CC
perhaps  ||| S:333 E:341 ||| RB
its  ||| S:341 E:345 ||| PRP$
most  ||| S:345 E:350 ||| RBS
important  ||| S:350 E:360 ||| JJ
use  ||| S:360 E:364 ||| NN
is  ||| S:364 E:367 ||| VBZ
in  ||| S:367 E:370 ||| IN
identifying  ||| S:370 E:382 ||| VBG
agents  ||| S:382 E:389 ||| NNS
that  ||| S:389 E:394 ||| WDT
will  ||| S:394 E:399 ||| MD
not  ||| S:399 E:403 ||| RB
work ||| S:403 E:407 ||| VB
,  ||| S:407 E:409 ||| ,
i.e. ||| S:409 E:413 ||| FW
,  ||| S:413 E:415 ||| ,
to  ||| S:415 E:418 ||| TO
detect  ||| S:418 E:425 ||| VB
resistance ||| S:425 E:435 ||| NN
.  ||| S:435 E:437 ||| .
Standardized  ||| S:437 E:450 ||| JJ
methods  ||| S:450 E:458 ||| NNS
for  ||| S:458 E:462 ||| IN
reliable  ||| S:462 E:471 ||| JJ
in  ||| S:471 E:474 ||| IN
vitro  ||| S:474 E:480 ||| JJ
antifungal  ||| S:480 E:491 ||| JJ
susceptibility  ||| S:491 E:506 ||| JJ
testing  ||| S:506 E:514 ||| NN
are  ||| S:514 E:518 ||| VBP
now  ||| S:518 E:522 ||| RB
available  ||| S:522 E:532 ||| JJ
from  ||| S:532 E:537 ||| IN
the  ||| S:537 E:541 ||| DT
Clinical  ||| S:541 E:550 ||| NNP
and  ||| S:550 E:554 ||| CC
Laboratory  ||| S:554 E:565 ||| NNP
Standards  ||| S:565 E:575 ||| NNPS
Institute  ||| S:575 E:585 ||| NNP
( ||| S:585 E:586 ||| -LRB-
CLSI ||| S:586 E:590 ||| NNP
)  ||| S:590 E:592 ||| -RRB-
in  ||| S:592 E:595 ||| IN
the  ||| S:595 E:599 ||| DT
United  ||| S:599 E:606 ||| NNP
States  ||| S:606 E:613 ||| NNPS
and  ||| S:613 E:617 ||| CC
the  ||| S:617 E:621 ||| DT
European  ||| S:621 E:630 ||| NNP
Committee  ||| S:630 E:640 ||| NNP
on  ||| S:640 E:643 ||| IN
Antimicrobial  ||| S:643 E:657 ||| NNP
Susceptibility  ||| S:657 E:672 ||| NNP
Testing  ||| S:672 E:680 ||| NNP
( ||| S:680 E:681 ||| -LRB-
EUCAST ||| S:681 E:687 ||| NNP
)  ||| S:687 E:689 ||| -RRB-
in  ||| S:689 E:692 ||| IN
Europe ||| S:692 E:698 ||| NNP
.  ||| S:698 E:700 ||| .
Data  ||| S:700 E:705 ||| NNP
gathered  ||| S:705 E:714 ||| VBD
by  ||| S:714 E:717 ||| IN
these  ||| S:717 E:723 ||| DT
standardized  ||| S:723 E:736 ||| JJ
tests  ||| S:736 E:742 ||| NNS
are  ||| S:742 E:746 ||| VBP
useful  ||| S:746 E:753 ||| JJ
( ||| S:753 E:754 ||| -LRB-
in  ||| S:754 E:757 ||| IN
conjunction  ||| S:757 E:769 ||| NN
with  ||| S:769 E:774 ||| IN
other  ||| S:774 E:780 ||| JJ
forms  ||| S:780 E:786 ||| NNS
of  ||| S:786 E:789 ||| IN
data ||| S:789 E:793 ||| NNS
)  ||| S:793 E:795 ||| -RRB-
for  ||| S:795 E:799 ||| IN
calculating  ||| S:799 E:811 ||| VBG
clinical  ||| S:811 E:820 ||| JJ
breakpoints  ||| S:820 E:832 ||| NN
and  ||| S:832 E:836 ||| CC
epidemiologic  ||| S:836 E:850 ||| JJ
cutoff  ||| S:850 E:857 ||| NN
values  ||| S:857 E:864 ||| NNS
( ||| S:864 E:865 ||| -LRB-
ECVs ||| S:865 E:869 ||| NNP
) ||| S:869 E:870 ||| -RRB-
.  ||| S:870 E:872 ||| .
Clinical  ||| S:872 E:881 ||| JJ
breakpoints  ||| S:881 E:893 ||| NN
should  ||| S:893 E:900 ||| MD
be  ||| S:900 E:903 ||| VB
selected  ||| S:903 E:912 ||| VBN
to  ||| S:912 E:915 ||| TO
optimize  ||| S:915 E:924 ||| VB
detection  ||| S:924 E:934 ||| VBN
of  ||| S:934 E:937 ||| IN
non-wild-type  ||| S:937 E:951 ||| NNP
( ||| S:951 E:952 ||| -LRB-
WT ||| S:952 E:954 ||| NNP
)  ||| S:954 E:956 ||| -RRB-
strains  ||| S:956 E:964 ||| NNS
of  ||| S:964 E:967 ||| IN
pathogens ||| S:967 E:976 ||| NN
,  ||| S:976 E:978 ||| ,
and  ||| S:978 E:982 ||| CC
they  ||| S:982 E:987 ||| PRP
should  ||| S:987 E:994 ||| MD
be  ||| S:994 E:997 ||| VB
species-specific  ||| S:997 E:1014 ||| JJ
and  ||| S:1014 E:1018 ||| CC
not  ||| S:1018 E:1022 ||| RB
divide  ||| S:1022 E:1029 ||| VBP
WT  ||| S:1029 E:1032 ||| JJ
distributions  ||| S:1032 E:1046 ||| NNS
of  ||| S:1046 E:1049 ||| IN
important  ||| S:1049 E:1059 ||| JJ
target  ||| S:1059 E:1066 ||| NN
species ||| S:1066 E:1073 ||| NNS
.  ||| S:1073 E:1075 ||| .
ECVs  ||| S:1075 E:1080 ||| NNS
are  ||| S:1080 E:1084 ||| VBP
the  ||| S:1084 E:1088 ||| DT
most  ||| S:1088 E:1093 ||| RBS
sensitive  ||| S:1093 E:1103 ||| JJ
means  ||| S:1103 E:1109 ||| NNS
of  ||| S:1109 E:1112 ||| IN
identifying  ||| S:1112 E:1124 ||| VBG
strains  ||| S:1124 E:1132 ||| NNS
with  ||| S:1132 E:1137 ||| IN
acquired  ||| S:1137 E:1146 ||| JJ
resistance  ||| S:1146 E:1157 ||| NN
mechanisms ||| S:1157 E:1167 ||| NNS
.  ||| S:1167 E:1169 ||| .
Various  ||| S:1169 E:1177 ||| JJ
mechanisms  ||| S:1177 E:1188 ||| NNS
can  ||| S:1188 E:1192 ||| MD
lead  ||| S:1192 E:1197 ||| VB
to  ||| S:1197 E:1200 ||| TO
acquired  ||| S:1200 E:1209 ||| JJ
resistance  ||| S:1209 E:1220 ||| NN
of  ||| S:1220 E:1223 ||| IN
Candida  ||| S:1223 E:1231 ||| NNP
species  ||| S:1231 E:1239 ||| NNS
to  ||| S:1239 E:1242 ||| TO
azole  ||| S:1242 E:1248 ||| VB
drugs ||| S:1248 E:1253 ||| NNS
,  ||| S:1253 E:1255 ||| ,
the  ||| S:1255 E:1259 ||| DT
most  ||| S:1259 E:1264 ||| RBS
common  ||| S:1264 E:1271 ||| JJ
being  ||| S:1271 E:1277 ||| VBG
induction  ||| S:1277 E:1287 ||| NN
of  ||| S:1287 E:1290 ||| IN
the  ||| S:1290 E:1294 ||| DT
efflux  ||| S:1294 E:1301 ||| JJ
pumps  ||| S:1301 E:1307 ||| NNS
encoded  ||| S:1307 E:1315 ||| VBN
by  ||| S:1315 E:1318 ||| IN
the  ||| S:1318 E:1322 ||| DT
MDR  ||| S:1322 E:1326 ||| NNP
or  ||| S:1326 E:1329 ||| CC
CDR  ||| S:1329 E:1333 ||| NNP
genes ||| S:1333 E:1338 ||| NNS
,  ||| S:1338 E:1340 ||| ,
and  ||| S:1340 E:1344 ||| CC
acquisition  ||| S:1344 E:1356 ||| NN
of  ||| S:1356 E:1359 ||| IN
point  ||| S:1359 E:1365 ||| NN
mutations  ||| S:1365 E:1375 ||| NNS
in  ||| S:1375 E:1378 ||| IN
the  ||| S:1378 E:1382 ||| DT
gene  ||| S:1382 E:1387 ||| NN
encoding  ||| S:1387 E:1396 ||| NN
for  ||| S:1396 E:1400 ||| IN
the  ||| S:1400 E:1404 ||| DT
target  ||| S:1404 E:1411 ||| NN
enzyme  ||| S:1411 E:1418 ||| NNS
( ||| S:1418 E:1419 ||| -LRB-
ERG11 ||| S:1419 E:1424 ||| NNP
) ||| S:1424 E:1425 ||| -RRB-
.  ||| S:1425 E:1427 ||| .
Acquired  ||| S:1427 E:1436 ||| VBN
resistance  ||| S:1436 E:1447 ||| NN
of  ||| S:1447 E:1450 ||| IN
Candida  ||| S:1450 E:1458 ||| NNP
species  ||| S:1458 E:1466 ||| NNS
to  ||| S:1466 E:1469 ||| TO
echinocandins  ||| S:1469 E:1483 ||| NN
is  ||| S:1483 E:1486 ||| VBZ
typically  ||| S:1486 E:1496 ||| RB
mediated  ||| S:1496 E:1505 ||| VBN
via  ||| S:1505 E:1509 ||| IN
acquisition  ||| S:1509 E:1521 ||| NN
of  ||| S:1521 E:1524 ||| IN
point  ||| S:1524 E:1530 ||| NN
mutations  ||| S:1530 E:1540 ||| NNS
in  ||| S:1540 E:1543 ||| IN
the  ||| S:1543 E:1547 ||| DT
FKS  ||| S:1547 E:1551 ||| NNP
genes  ||| S:1551 E:1557 ||| NNS
encoding  ||| S:1557 E:1566 ||| VBP
the  ||| S:1566 E:1570 ||| DT
major  ||| S:1570 E:1576 ||| JJ
subunit  ||| S:1576 E:1584 ||| NN
of  ||| S:1584 E:1587 ||| IN
its  ||| S:1587 E:1591 ||| PRP$
target  ||| S:1591 E:1598 ||| NN
enzyme ||| S:1598 E:1604 ||| NN
.  ||| S:1604 E:1606 ||| .
Antifungal  ||| S:1606 E:1617 ||| JJ
resistance  ||| S:1617 E:1628 ||| NN
is  ||| S:1628 E:1631 ||| VBZ
associated  ||| S:1631 E:1642 ||| VBN
with  ||| S:1642 E:1647 ||| IN
elevated  ||| S:1647 E:1656 ||| JJ
minimum  ||| S:1656 E:1664 ||| JJ
inhibitory  ||| S:1664 E:1675 ||| JJ
concentrations ||| S:1675 E:1689 ||| NNS
,  ||| S:1689 E:1691 ||| ,
poorer  ||| S:1691 E:1698 ||| JJR
clinical  ||| S:1698 E:1707 ||| JJ
outcomes ||| S:1707 E:1715 ||| NNS
,  ||| S:1715 E:1717 ||| ,
and  ||| S:1717 E:1721 ||| CC
breakthrough  ||| S:1721 E:1734 ||| NN
infections  ||| S:1734 E:1745 ||| NNS
during  ||| S:1745 E:1752 ||| IN
antifungal  ||| S:1752 E:1763 ||| JJ
treatment  ||| S:1763 E:1773 ||| NN
and  ||| S:1773 E:1777 ||| CC
prophylaxis ||| S:1777 E:1788 ||| NN
.  ||| S:1788 E:1790 ||| .
Candidemia  ||| S:1790 E:1801 ||| JJ
due  ||| S:1801 E:1805 ||| JJ
to  ||| S:1805 E:1808 ||| TO
Candida  ||| S:1808 E:1816 ||| NNP
glabrata  ||| S:1816 E:1825 ||| NN
is  ||| S:1825 E:1828 ||| VBZ
becoming  ||| S:1828 E:1837 ||| VBG
increasingly  ||| S:1837 E:1850 ||| RB
common ||| S:1850 E:1856 ||| JJ
,  ||| S:1856 E:1858 ||| ,
and  ||| S:1858 E:1862 ||| CC
C  ||| S:1862 E:1864 ||| $
glabrata  ||| S:1864 E:1873 ||| CD
isolates  ||| S:1873 E:1882 ||| NNS
are  ||| S:1882 E:1886 ||| VBP
increasingly  ||| S:1886 E:1899 ||| RB
resistant  ||| S:1899 E:1909 ||| JJ
to  ||| S:1909 E:1912 ||| TO
both  ||| S:1912 E:1917 ||| DT
azole  ||| S:1917 E:1923 ||| NN
and  ||| S:1923 E:1927 ||| CC
echinocandin  ||| S:1927 E:1940 ||| JJ
antifungal  ||| S:1940 E:1951 ||| JJ
agents ||| S:1951 E:1957 ||| NNS
.  ||| S:1957 E:1959 ||| .
This  ||| S:1959 E:1964 ||| DT
situation  ||| S:1964 E:1974 ||| NN
requires  ||| S:1974 E:1983 ||| VBZ
continuing  ||| S:1983 E:1994 ||| VBG
attention ||| S:1994 E:2003 ||| NN
.  ||| S:2003 E:2005 ||| .
Rates  ||| S:2005 E:2011 ||| NNS
of  ||| S:2011 E:2014 ||| IN
azole-resistant  ||| S:2014 E:2030 ||| NNP
Aspergillus  ||| S:2030 E:2042 ||| NNP
fumigatus  ||| S:2042 E:2052 ||| NNS
are  ||| S:2052 E:2056 ||| VBP
currently  ||| S:2056 E:2066 ||| RB
low ||| S:2066 E:2069 ||| JJ
,  ||| S:2069 E:2071 ||| ,
but  ||| S:2071 E:2075 ||| CC
there  ||| S:2075 E:2081 ||| EX
are  ||| S:2081 E:2085 ||| VBP
reports  ||| S:2085 E:2093 ||| NNS
of  ||| S:2093 E:2096 ||| IN
emerging  ||| S:2096 E:2105 ||| VBG
resistance ||| S:2105 E:2115 ||| NN
,  ||| S:2115 E:2117 ||| ,
including  ||| S:2117 E:2127 ||| VBG
multi-azole  ||| S:2127 E:2139 ||| JJ
resistant  ||| S:2139 E:2149 ||| JJ
isolates  ||| S:2149 E:2158 ||| NN
in  ||| S:2158 E:2161 ||| IN
parts  ||| S:2161 E:2167 ||| NNS
of  ||| S:2167 E:2170 ||| IN
Europe ||| S:2170 E:2176 ||| NNP
.  ||| S:2176 E:2178 ||| .
